Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 4/2012

01-08-2012 | Psychiatry in Primary Care (BN Gaynes, Section Editor)

How Should Primary Care Doctors Select Which Antidepressants to Administer?

Authors: Gerald Gartlehner, Kylie Thaler, Seth Hill, Richard A. Hansen

Published in: Current Psychiatry Reports | Issue 4/2012

Login to get access

Abstract

Clinicians can choose among various second-generation antidepressants for treating depressive disorders, such as major depressive disorder, subsyndromal depression, or dysthymia. Systematic reviews indicate that available drugs differ in frequency of administration, costs, and the risks of some adverse events but have similar efficacy for treating major depressive disorder. Furthermore, evidence does not support the choice of one antidepressant over another based on accompanying symptoms, such anxiety, insomnia, or pain. Available studies provide little guidance for clinicians about the benefits of second-generation antidepressants for treating dysthymia and subsyndromal depression. Evidence is also unclear about the comparative risks of serious adverse events, such as suicidality, seizures, fractures, increased bleeding, or serotonin syndrome. This article summarizes the best available evidence regarding comparative benefits and harms of second-generation antidepressants for treating depressive disorders.
Literature
1.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision. Washington, DC. 2000.
2.
Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):593–602.PubMedCrossRef
3.
Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848–56.PubMedCrossRef
4.
Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465–75.PubMedCrossRef
5.
Birnbaum HG, Ben-Hamadi R, Greenberg PE, et al. Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. Pharmacoeconomics. 2009;27(6):507–17.PubMedCrossRef
6.
Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52(Suppl):28–34.PubMed
7.
Berkrot B. US prescription drug sales hit $300 bln in 2009, e. Gary Hill, Editor 2010, Reuters.
8.
Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132(9):743–56.PubMed
9.
Geddes JR, Freemantle N, Mason J et al. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. The Cochrane Library (Cochrane Review), 2006(1).
10.
Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143(6):415–26.PubMed
11.
Cipriani A, Furukawa TA, Geddes JR et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis, in J Clin Psychiatry 2008; 1732–42.
12.
Omori IM, Watanabe N, Nakagawa A et al. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: Meta-analysis. Journal of Psychopharmacology 2009; 539–550.
13.
Watanabe N, Omori IM, Nakagawa A et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis, in Journal of Clinical Psychiatry 2008; 1404–1415.
14.
Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl). 2008;196(4):511–20. discussion 521–2.CrossRef
15.
Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol. 2009;24(3):177–90.PubMedCrossRef
16.
Eckert L, Falissard B. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Curr Med Res Opin 2006;2313–21.
17.
Eckert L and Lançon C. Duloxetine compared with fluoxetine and venlafaxine: Use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006.
18.
•• Gartlehner G, Hansen RA, Morgan LC, et al. Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder: An Updated Meta-analysis. Ann Intern Med. 2011;155(11):772–85. This is the most recent and most comprehensive assessment of the comparative efficacy and safety of second-generation antidepressants for the treatment of depressive disorders..PubMed
19.
Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;746–58.
20.
Turner E, Moreno SG, Sutton AJ. Ranking antidepressants. Lancet. 2009;373(9677):1760. author reply 1761–2.PubMedCrossRef
21.
Seyringer ME, Kasper S. Ranking antidepressants. Lancet. 2009;373(9677):1760–1. author reply 1761–2.PubMedCrossRef
22.
23.
24.
Gartlehner G, Gaynes BN, Hansen RA, Lohr KN. Ranking antidepressants. Lancet. 2009;373(9677):1761. author reply 1761–2.PubMedCrossRef
25.
Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. AHRQ. 2011;46:171.
26.
Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61(9):656–63.PubMedCrossRef
27.
Schatzberg AF, Kremer C, Rodrigues HE, Murphy Jr GM. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10(5):541–50.PubMed
28.
Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23(4):358–64.PubMedCrossRef
29.
Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry. 2003;64(8):921–6.PubMedCrossRef
30.
Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137–46.PubMedCrossRef
31.
Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59(6):306–12.PubMedCrossRef
32.
Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol. 1999;14(6):329–37.PubMedCrossRef
33.
Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry. 1999;11(4):205–15.PubMed
34.
Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21(4):643–58.PubMedCrossRef
35.
Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry. 1997;58(12):532–7.PubMedCrossRef
36.
Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991;52(8):329–35.PubMed
37.
Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther. 2001;23(7):1040–58.PubMedCrossRef
38.
Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 2007; 245–50.
39.
Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;736–46.
40.
Kennedy SH, Fulton KA, Bagby RM et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;234–42.
41.
Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(10):725–33.PubMed
42.
Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–9.PubMedCrossRef
43.
Kim HM, Zivin K, Ganoczy D, et al. Predictors of alternative antidepressant agent initiation among U. S. veterans diagnosed with depression. Pharmacoepidemiol Drug Saf. 2010;19(10):1049–56.PubMedCrossRef
44.
Garrison GD, Levin GM. Factors affecting prescribing of the newer antidepressants. Ann Pharmacother. 2000;34(1):10–4.PubMedCrossRef
45.
46.
Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry. 1999;60(1):22–8.PubMedCrossRef
47.
De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002;5(2):115–20.PubMed
48.
Sir A, D’Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66(10):1312–20.PubMedCrossRef
49.
Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology. 2001;25(1):131–8.PubMedCrossRef
50.
Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry. 1996;57 Suppl 2:46–52.PubMed
51.
Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry. 1997;58(5):185–92.PubMedCrossRef
52.
Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99–106.PubMedCrossRef
53.
Beasley Jr CM, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294–9.PubMed
54.
Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14(6):457–70.PubMedCrossRef
55.
Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24(4):389–99.PubMedCrossRef
56.
Perahia DG, Wang F, Mallinckrodt CH et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 367–78.
57.
58.
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry, 2000; 157(4 Suppl):1–45.
59.
Hansen R, Gaynes B, Thieda P et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 2008;1121–30.
60.
Bauer M, Tharmanathan P, Volz HP et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;172–85.
61.
Soares CN, Thase ME, Clayton A et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;700–11.
62.
Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;159–69.
63.
Van Moffaert M, Bartholome F, Cosyns P, De Nayer AR. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol. 1995;10:393–405.CrossRef
64.
Keller MB, Trivedi MH, Thase ME et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007; 1246–56.
65.
Franchini L, Gasperini M, Zanardi R, Smeraldi E. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord. 2000;58(3):233–6.PubMedCrossRef
66.
Franchini L, Gasperini M, Perez J, et al. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry. 1997;58(3):104–7.PubMedCrossRef
67.
Lin CC. Duloxetine treatment of social anxiety disorder with comorbid major depression. J Clin Psychopharmacol. 2008;28(5):591–2. author reply 592–3.PubMedCrossRef
68.
Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry 2006;1905–17.
69.
Trivedi MH, Fava M, Wisniewski SR. et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;1243–52.
70.
Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol. 2012;32(1):114–9.PubMedCrossRef
71.
Fang Y, Yuan C, Xu Y et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol 2010;357–64.
72.
Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12–6.PubMedCrossRef
73.
Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008;23(3):113–9.PubMedCrossRef
74.
Corya SA, Williamson D, Sanger TM et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;364–72.
75.
Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005;22(2):68–76.PubMedCrossRef
76.
Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–8.PubMedCrossRef
77.
Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183–8.PubMedCrossRef
78.
Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65(3):337–40.PubMedCrossRef
79.
Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;457–65.
80.
Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689–701.PubMedCrossRef
81.
Vanelle JM, Attar-Levy D, Poirier MF, et al. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry. 1997;170:345–50.PubMedCrossRef
82.
Kocsis JH, Zisook S, Davidson J, et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry. 1997;154(3):390–5.PubMed
83.
Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 1996;53(9):777–84.PubMedCrossRef
84.
Devanand DP, Nobler MS, Cheng J, et al. Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. Am J Geriatr Psychiatry. 2005;13(1):59–68.PubMed
85.
Barrett JE, Williams Jr JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract. 2001;50(5):405–12.PubMed
86.
Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry. 2000;61(11):821–7.PubMedCrossRef
87.
Williams Jr JW, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA. 2000;284(12):1519–26.PubMedCrossRef
88.
Kroenke K. Minor depression: midway between major depression and euthymia. Ann Intern Med. 2006;144(7):528–30.PubMed
89.
Cuijpers P, Smit F. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. Acta Psychiatr Scand. 2004;109(5):325–31.PubMedCrossRef
90.
Judd LL, Rapaport MH, Yonkers KA, et al. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry. 2004;161(10):1864–71.PubMedCrossRef
91.
Rocca P, Calvarese P, Faggiano F, et al. Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. J Clin Psychiatry. 2005;66(3):360–9.PubMedCrossRef
92.
Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry. 2002;47(4):375–7.PubMed
93.
Strombom I, Wernicke JF, Seeger J, et al. Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources. Curr Drug Saf. 2008;3(2):154–62.PubMedCrossRef
94.
Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396.PubMedCrossRef
95.
Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol. 2005;60(5):519–25.PubMedCrossRef
96.
Rahme E, Dasgupta K, Turecki G et al. Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study. J Clin Psychiatry 2008;349–57.
97.
Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007;356(23):2343–6.PubMedCrossRef
98.
• Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180(3):291–7. Suicidal attempts or suicides are rare but severe adverse effects of second-generation antidepressants. Randomized controlled trials are usually too small to assess the excess risk of suicidality. This study provides a meta-analyses of large observational studies..PubMedCrossRef
99.
Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ. 2005;330(7488):385.PubMedCrossRef
100.
Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338–43.PubMedCrossRef
101.
Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790–2.PubMedCrossRef
102.
Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case–control study. BMJ. 2005;330(7488):389.PubMedCrossRef
Metadata
Title
How Should Primary Care Doctors Select Which Antidepressants to Administer?
Authors
Gerald Gartlehner
Kylie Thaler
Seth Hill
Richard A. Hansen
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Psychiatry Reports / Issue 4/2012
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-012-0283-x

Other articles of this Issue 4/2012

Current Psychiatry Reports 4/2012 Go to the issue

Eating Disorders (E Attia, Section Editor)

What can Cognitive Neuroscience Teach us about Anorexia Nervosa?

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Addressing Suicidality in Primary Care Settings

Invited Commentary

Eating Disorders: Some New Answers to Old Questions

Geriatric Disorders (Dc Steffens, Section Editor)

Mild Cognitive Impairment in Older Adults

Geriatric Disorders (DC Steffens, Section Editor)

Treatment of Depression in Older Adults

Eating Disorders (E Attia, Section Editor)

Adolescent Bulimia Nervosa